NCT00296725View on ClinicalTrials.gov

Dichotic Listening as a Predictor of Medication Response in Depression

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 30, 1994

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Major DepressionDysthymiaDepressive Disorder Not Otherwise Specified
Interventions
DRUG

Fluoxetine

Phase 1: Fluoxetine: wk 1: 10 mg/day; wks 2-3: 20 mg/day; wks 4-5: 40 mg/day; wk 6: 60 mg/day; wks 7-12: 80 mg/day \*All increases only if tolerated.

DRUG

Imipramine

Phase 2: Imipramine wk 1: 25 mg/day; wk 2: 50 mg/day; wk 3: 100 mg/day, 150 mg/day after 3 days; wk 4: 200 mg/day, 250 mg/day after 3 days; wks 5-6: 300 mg/day. \*All increases only if tolerated.

Trial Locations (1)

10032

Depression Evaluation Service, New York State Psychiatric Institute, New York

All Listed Sponsors
lead

New York State Psychiatric Institute

OTHER

NCT00296725 - Dichotic Listening as a Predictor of Medication Response in Depression | Biotech Hunter | Biotech Hunter